Cost-Consequence Analysis of Using Cangrelor in High Angiographic Risk Percutaneous Coronary Intervention Patients: A US Hospital Perspective.

ABSTRACT:

Objectives

The objective of this study was to evaluate a US hospital's cost implications and outcomes of cangrelor use in percutaneous coronary intervention (PCI) patients with two or more angiographic high-risk features (HRFs), including avoidance of oral P2Y₁₂ inhibitor pretreatment in patients requiring cardiac surgery. Intravenous cangrelor provides direct, immediate onset and rapid-offset P2Y₁₂ inhibition, which may reduce the necessity for oral P2Y₁₂ pretreatment.

Methods

A decision analytic model was developed, estimating the annual impact over 3 years of cangrelor availability. Ischemic and bleeding events (48 h) from randomized clinical trial data were extrapolated to 30 days. Event costs were from the CHAMPION PHOENIX Economics subs

SUBMITTER: Jensen IS 

PROVIDER: S-EPMC8748330 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature